<DOC>
	<DOC>NCT00865449</DOC>
	<brief_summary>This is a double blind randomized controlled study to evaluate the effect of aldactone on peritoneal fibrosis on incident peritoneal dialysis patients. The study would include a total of 40 incident peritoneal dialysis patients. Peritoneal biopsy would be made at randomization and 6 months after the intervention to evaluate the effect of renin angiotensin blockade on peritoneal fibrosis.</brief_summary>
	<brief_title>Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Peritoneal Fibrosis</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Age &gt; 18 Hospitalized for peritoneal catheter placement for peritoneal dialysis Pregnancy Hiperkalemia (K&gt; 5.5meq/l) Intolerance to spironolactone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>spironolactone</keyword>
	<keyword>peritoneal fibrosis</keyword>
	<keyword>peritoneal dialysis</keyword>
</DOC>